CTIS2022-501184-41-00进行中（未招募）1 期
A phase IV randomised, double-blind, parallel-design, controlled multi-center trial of a NOVel moisturiser for Atopic dermatitis: effect on relapse prevention in children, NOVA II
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •Children >2- =12 years old (male and female), Diagnosis of AD according to UK working party 1994,(32) i.e.: a) Any itching skin condition and b) Three or more of the following: (i) History of flexural involvement, e.g. front of elbows, behind the knees, front of ankles, around the neck (ii) Personal history of other atopic disease, e.g. asthma or hay fever (iii) History of generally dry skin in the last 12 months (iv) Visible flexural dermatitis, e.g. front of elbows, behind the knees, front of ankles, around the neck (v) Onset below age 2, Visible mild (= 15 ) to moderate (> 15 to < 40) eczema according to the objective SCORAD, which ideally should be symmetrical in localization and/or face., Participants with at least two relapses during last 12 months, including the one at the screening visit, Participants willing to agree to avoid any other prescription/OTC/natural remedies treatments for eczema and/or dry skin, Legally acceptable representatives (i.e. parent(s) or guardians) of participant according to local regulations have provided the appropriate written informed consent and participant has given their assent (as age appropriate).
排除标准
- •Participants with severe eczema, as defined by objective SCORAD, Any treatment with immunomodulatory systemic medications, e.g. dupilumab, omalizumab or other biologics, JAK inhibitors, methotrexate, cyclosporine, oral or systemic corticosteroids (except inhaled corticoid spray for allergic asthma if on a stable dose and asthma status well controlled) within 3 months prior screening and throughout the study, Any treatment with TCS' (other than the corticosteroids prescribed in the stabilisation phase) or other established topical treatment for AD within 2 weeks prior screening and throughout the study., Phototherapy (UVB, UVA, UVA1, PUVA) within 4 weeks prior screening and throughout the study, Moisturisers, home remedies or other topical products on the study area eczemas, except for the AxMP (during the stabilisation phase) and the IP in the maintenance phase., Asthma which is not stable during the last 6 months prior screening as per clinical judgement (reflected by symptoms>2 days per week or nighttime awakening with symptoms > 2 times per week or reduced normal activities due to asthma, PEF <80% of predicted value), Any infectious disease of the skin within 4 weeks prior screening, Viral diseases (e.g. chicken pocks, shingles), rosacea, perioral dermatitis, ulcers, acne vulgaris,skin atrophy, vaccination reaction in the treatment area, Skin infections caused by bacteria and fungi, Diaper rash in the treatment area, Any infectious disease including unexplained diarrhea within 2 weeks prior screening, Participants with eczema on the hands only, Any immunosuppression or history of unusual frequent, recurrent, severe or prolonged infections, History of immunomodulatory or immunosuppressant diseases e.g. lymphoproliferative diseases, diabetes mellitus, malignancies of any organ within 5 years prior screening, History of intolerance to topical corticosteroids or any condition which prohibits or does not recommend treatment with topical corticosteroids e.g. atrophy of the skin, Participants with known or suspected allergies or contraindications to any of the study product ingredients (including products for the treatment in the stabilization phase), Participants/participants’ parent(s) and/or legal guardian(s) who, in the opinion of the Investigator, are unable to complete all study related visits and/or procedures., Pregnancy confirmed by a positive human chorionic gonadotropin (hCG) urine test for females of childbearing potential, Enrolment in any investigational study or use of an investigational product (oral or topical) within 3 months prior to the screening visit, Planning to participate in any other clinical study during participation in this current study, including the maintenance phase., Participants unwilling to refrain from using prohibited medication including moisturizers (other than the study treatments), Antibiotic, antimycotic or antiviral treatment (oral or topical) within 2 weeks prior screening and throughout the study
研究者
相似试验
进行中（未招募）
1 期
Commercial study conducted to determine the most adequate supplementation of vitamin D in patients showing vitamin D deficiencyPatients of 18 years of age or more with vitamin D deficiencyMedDRA version: 14.1Level: PTClassification code 10047626Term: Vitamin D deficiencySystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-004917-14-BEABORATOIRES SMB S.A
进行中（未招募）
1 期
Clinical study assessing interchangeability between SB5 and Humira in patients with moderate to severe chronic plaque psoriasis.Moderate to severe plaque psioriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2022-000695-19-LTSamsung Bioepis Co., Ltd366
进行中（未招募）
不适用
A randomized, double-blind, monocentric phase IV clinical study on the ocular tolerability of a topical ophthalmic product containing Retinolpalmitat 1000 I.U. in comparison to a reference product containing Carbomer 0.2 % with repeated ocular applications over 12 months in 120 patients with keratoconjunctivitis sicca - ocular tolerability of a topical ophthalmic product containing Retinolpalmitat 1000 I.U.Patients suffering from keratoconjunctivitis sicca (dry eye) and break-up-time (BUT) values < 10 secEUCTR2006-000991-34-DEDr. Gerhard Mann, Chem-pharm. Fabrik GmbH120
进行中（未招募）
1 期
A pharmacological study on efficacy and safety of OM-85 in children with recurrent respiratory tract infectionsEUCTR2016-002705-19-ITFONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO288
进行中（未招募）
1 期
A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/day per os for 12 weeks to investigate the effects on RLS symptoms (IRLS) and sleep disturbance (MOS sleep scale) in out-patients with idiopathic Restless Legs SyndromeEUCTR2005-005225-54-DKBoehringer Ingelheim Italia S.p.A.-Milan430